T 2045/09 (Anti-ErbB3 antibody/GENENTECH) of 14.05.2014
- European Case Law Identifier
- ECLI:EP:BA:2014:T204509.20140514
- Date of decision
- 14 May 2014
- Case number
- T 2045/09
- Petition for review of
- -
- Application number
- 97908923.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Erbb3 antibodies
- Applicant name
- Genentech, Inc.
- Opponent name
- Amgen Inc.
U3 Pharma GmbH
Merrimack Pharmaceuticals, Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84European Patent Convention R 139Rules of procedure of the Boards of Appeal Art 13(3)
- Keywords
- Admissibility of appeal - appeal admissible after remedy of deficiencies
Inventive step - Main request (no)
Late-filed auxiliary requests - admitted (yes)
Amendment - added subject-matter
Amendment - Auxiliary request 1 (yes)
Claims - unclear characterization of parameters
Claims - Auxiliary request 2 (yes)
Amendment - added subject-matter
Amendment - Auxiliary request 3 (no)
Inventive step - Auxiliary request 3 (yes) - Catchword
- -
Order
For these reasons it is decided that:
The appeals of all parties are dismissed.